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Abstract: The adhesion and traction behavior of leukemia cells in their microenvironment is 
directly linked to their migration, which is a prime issue affecting the release of cancer cells from 
the bone marrow and hence metastasis. In assessing the effectiveness of phorbol 12-myristate 
13-acetate (PMA) treatment, the conventional batch-cell transwell-migration assay may not 
indicate the intrinsic effect of the treatment on migration, since the treatment may also affect 
other cellular behavior, such as proliferation or death. In this study, the pN-level adhesion and 
traction forces between single leukemia cells and their microenvironment were directly mea-
sured using optical tweezers and traction-force microscopy. The effects of PMA on K562 and 
THP1 leukemia cells were studied, and the results showed that PMA treatment significantly 
increased cell adhesion with extracellular matrix proteins, bone marrow stromal cells, and 
human fibroblasts. PMA treatment also significantly increased the traction of THP1 cells on 
bovine serum albumin proteins, although the effect on K562 cells was insignificant. Western 
blots showed an increased expression of E-cadherin and vimentin proteins after the leukemia 
cells were treated with PMA. The study suggests that PMA upregulates adhesion and thus 
suppresses the migration of both K562 and THP1 cells in their microenvironment. The ability 
of optical tweezers and traction-force microscopy to measure directly pN-level cell–protein or 
cell–cell contact was also demonstrated.
Keywords: adhesion, migration, cell-to-cell contact, optical trapping, traction-force microscopy, 
protein micropillar matrix
Introduction
The regulatory mechanism of hematopoietic stem cell (HSC)-niche maintenance is 
still a mystifying field to be uncovered,1 and understanding the biomechanics of how 
HSCs or abnormal leukocytes interact with their surrounding microenvironment would 
help elucidate the underlying issues. Bone marrow stromal cells (BMSCs), including 
osteoblasts, endothelial cells, and fibroblasts (FBs), and extracellular matrix proteins 
(ECMPs), such as collagens, glycoproteins (fibronectin, laminins, and vitronectin), 
proteoglycans, and glycosaminoglycans, coexist with the SCs and leukocytes inside the 
BM, and they help regulate the self-renewal of HSCs and leukocytes and their release 
into the bloodstream.2 Cell proliferation, differentiation, and migration responses to 
the signal communication between HSCs, BMSCs, and ECMPs are mainly through 
adhesion molecules.3,4 Among those adhesion proteins, integrins and transmembrane 
proteoglycans are the main receptors and coreceptors for the matrix,5 while cadherins are 
adhesion proteins mediating cell–cell contact.6 It has been reported that low expression 
of E-cadherin adhesion proteins is implicated in the abnormal interaction of leukemic 
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cells with human BMSCs (hBMSCs),7 and regulating the 
migration of myelogenous leukemia cells leads to a change of 
interaction with the BMSCs.8 Collagen is the most abundant 
fibrous protein within the interstitial ECM,9 and fibronectin 
proteins have been shown to be able to induce endothelial 
cell migration through β
1
 integrin and Src-dependent phos-
phorylation of FB growth-factor receptor 1.10 Treatment of 
abnormal HSCs can lead to a different interaction with the 
BMSCs and ECMPs. As such, measuring alterations in the 
adhesion and traction behavior of drug-treated leukemia cells 
with their mimicked microenvironment can provide a new 
strategy for therapy assessment.
Phorbol 12-myristate 13-acetate (PMA)11 has been 
reported to be able to make certain myeloid leukemia cells, 
such as K562, HL60, and THP1, to differentiate into more 
mature cell types.12–15 However, little is known about the 
treatment effect of PMA on the release of leukemia cells 
from the BM after undergoing such differentiation therapy.16 
Therefore, the adhesion and migration of leukemia cells 
treated with and without PMA to a mimic ECM environ-
ment were investigated in this study. Chronic myelogenous 
leukemia K562 cells17 exhibit much less clumping than many 
other suspension cell lines during cell culture, presumably 
due to the downregulation of surface-adhesion molecules.18 
On the other hand, acute myelogenous leukemia THP1 cells19 
show rapid proliferation, which could lead to rapid expan-
sion at location areas and hence migration. This study aimed 
to show that after differentiation treatment with PMA, the 
migration and mobility of both types of leukemia cells in the 
mimic microenvironment can be suppressed and a positive 
therapeutic outcome can be reached.
Although many batch-cell methods, such as Western blot 
and enzyme-linked immunosorbent assay, can detect the 
expression of proteins responsible for adhesion or migra-
tion, such protein expression serves only as an indirect 
indicator of the actual cellular adhesion or migration ability 
in the microenvironment. Direct measurements of cell–cell 
or cell–substrate interactions at the single cell level have 
been rare,20 despite the fact that knowing such interaction 
forces would help elucidate the effects of drug treatment in 
cell adhesion and migration. Optical tweezers21 and atomic 
force microscopy (AFM)22 have been established as effec-
tive tools for the measurement of cell–cell or cell–substrate 
interactions.20,23 In the present work, we employed optical 
tweezers to measure the adhesion property of leukemia cells 
on primary ECMPs fibronectin and collagen I, hBMSCs, 
and human FBs (hFBs), as well as bovine serum albumin 
(BSA). ECMPs and hFBs, such as hBMSCs, are important 
constituents of the BM microenvironment,24 which directly 
interacts with HSCs or leukemia cells,25 and so any change in 
their interaction with leukemia cells may affect the mobility 
and migration of the latter. As an inert protein, BSA was used 
as negative control to compare with other adhesion proteins 
like fibronectin, collagen I, or E-cadherin.
To elucidate the effect of the PMA on the traction force 
of leukemia cells, we employed traction-force microscopy to 
measure the traction force of leukemia cells on a BSA micro-
pillar matrix fabricated using a multiphoton, photochemical 
cross-linking technique.26,27 BSA was chosen, as it interacts 
with few proteins existing on the leukemia cells, and hence 
such a matrix can elucidate the intrinsic effects of a drug 
on the cell-traction force. To evaluate further the effects of 
the PMA on cell metastasis, Western blot analysis was also 
carried out to compare E-cadherin and vimentin expression 
before and after PMA treatment. The downregulation of 
E-cadherin expression and upregulation of vimentin expres-
sion are the primary events of epithelial–mesenchymal tran-
sition, and consequently promote metastasis,28,29 while high 
expression of E-cadherin protein is also thought to be one of 
the indicators for mesenchymal–epithelial transition,30 which 
is believed to reduce cell metastasis and cell migration.31
Materials and methods
cell culture
Myelogenous leukemia K562 cells and THP1 were cultured 
in a 25 mL culture flask with Gibco Roswell Park Memorial 
Institute (RPMI) 1640 medium premixed with 10% fetal 
bovine serum (FBS) and 1% penicillin–streptomycin, laid 
inside a 5% CO
2
 incubator (VS-9160C; Bionex, Seoul, 
South Korea) and maintained at a humidity of 95% and a 
temperature of 37°C for 48 hours before PMA treatment. 
In all the experiments, 1 mg/mL stock solution of the PMA 
was used and added to the cell-culture medium to reach a 
final concentration of 1 μg/mL. Approval for the use of cell 
lines was given by the Human Research Ethics Committee 
for Non-clinical Faculties of the University of Hong Kong 
(reference number: EA240913), who deemed patient written 
informed consent was not necessary.
adhesion assay
The leukemia cells treated with and without 1 μg/mL PMA 
were cultured in flasks in advance for 48 hours. The cells were 
trypsinized for 2 minutes, centrifuged, and resuspended in 
fresh Gibco RPMI 1640 medium with 10% FBS. The cells 
were then counted with a hemocytometer to a concentra-
tion of 1×106 cells/mL, and 100 μL of the culture medium 
containing the cells was added to each well of the 96-well 
microplates, which were precoated with 4 μg/mL BSA 
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proteins, fibronectin, collagen I, and Anti-E-cadherin (Sigma-
Aldrich, St Louis, MO, USA). The cells were incubated for 
30 minutes for cell attachment, and the remaining suspended 
cells were removed. The attached cells were measured using 
the MTT assay at 570 nm wavelength absorbance in an Asys 
UVM 340 microplate reader (Biochrom, Cambridge, UK).
Transwell-migration assay
The leukemia cells treated with and without PMA were cul-
tured for 48 hours, and the cells in the media with 10% FBS 
were put into fresh media without FBS and cultured further 
for 3 hours.32 The cells were then trypsinized and seeded at 
a density of 1×105 cells/well in the serum-free medium in 
the upper inserted chambers of a CytoSelect™ 96-well cell-
invasion assay (Cell Biolabs, San Diego, CA, USA), with the 
upper chambers precoated with 4 μg/mL BSA, fibronectin, 
collagen I, and anti-E-cadherin. The leukemia cells were 
chemoattracted by the medium containing 10% FBS in the 
lower chambers for 12 hours. The upper chambers were 
removed, and the cells in the lower chambers were measured 
using the MTT assay at 570 nm wavelength absorbance in 
the Asys microplate reader.
Optical tweezer manipulation in cell–
protein/cell–cell contact
Before the experiments, BSA, fibronectin, collagen I, and 
anti-E-cadherin with a final concentration of 30 μg/mL were 
mixed with a solution containing 1% 2 μm-diameter polysty-
rene beads (Bangs Laboratories, Fishers, IN, USA), follow-
ing a procedure described previously.23 Such a high protein 
concentration enabled the beads used in the optical tweezer-
manipulation experiments to be covered fully with proteins,23 
so that the protein–cell interactions could be characterized 
accurately in a repeatable fashion. In the experiments for 
measuring cell–protein interactions, leukemia cells with and 
without PMA treatment or transfected with fluorescein iso-
thiocyanate (FITC)-labeled SiR-E-cadherin by Lipofectamine 
2000 (Thermo Fisher Scientific, Waltham, MA, USA) were 
cultured for 48 hours in confocal dishes that were then brought 
into an Okolab mini-incubator placed on the stage of the optical 
tweezer system (Molecular Machines and Industries, Eching, 
Germany). The protein-coated beads were also added to the 
confocal dishes. In the experiments for measuring cell–cell 
interactions, the hBMSCs or hFBs were precultured in confocal 
dishes for 24 hours to enable the cells to spread well onto the 
substrate. K562 or THP1 cells treated with or without PMA 
for 48 hours were then added into the confocal dishes.
Before measurement of the cell–protein or cell–cell 
interactions, the maximum trapping force on either the 
protein-coated spheres or leukemia cells at different laser 
power needed to be calibrated. In the force-calibration pro-
cedure, the coated spheres or spherical leukemia cells were 
optically trapped and oscillated at different laser power to 
obtain the maximum trapping force at each laser power. 
At each laser power, the maximum laser trapping force 
F
max
 was obtained by Equation 1, by oscillating the trapped 
sphere or cell at increasing frequency ω or amplitude A
c
 until 
it broke away from the trap:23
 
F a
max
= 6 2π η ωA
c  
(1)
where η and a are the dynamic viscosity of the culture 
medium and radius of the sphere or cell, respectively. 
The maximum trapping force at different laser power was 
measured before the cell–protein and cell–cell interaction 
experiments. Adherent cells, such as hBMSCs and hFBs, 
would stick to the bottom of the confocal dish naturally, 
and some of the leukemia cells would also stick weakly to 
the bottom of the confocal dish. Then, in the actual interac-
tion experiments, a protein-coated sphere or leukemia cell 
was brought into contact with a leukemia cell, hBMSC, or 
hFB for 10 seconds, and was then pulled away at a speed of 
1 μm/second. By increasing the laser power until the trapped 
sphere or cell was completely separated from the contact-
ing cell, the maximum binding force of the cell–protein or 
cell–cell was obtained from the critical laser power at which 
breakaway just happened. Cell viability was not affected by 
laser power, not only because the laser power used in the 
experiments was low but also because the laser duration was 
very short: no more than 10 seconds. At the beginning of 
cell–cell contact, only a very low laser power was enough 
for the trapped cell to be attached to another cell. Further-
more, in the cell–protein interaction experiments, only the 
bead was trapped by laser. Therefore, cell viability and most 
importantly binding-force measurement was not influenced 
by the laser trap.
Western blots
The K562 and THP1 cells treated with or without PMA 
and the non-PMA-treated K562 and THP1 cells were cul-
tured in a 24-microwell plate in advance for 48 hours for 
cell attachment. The cells in the 24-microwell plate were 
then transfected with the FITC-labeled small- interfering 
RNA (siRNA) SiR-E-cadherin (CDH1 E-cadherin, 
sequence 5′-GACAAUGGUUCUCCAGUUG-3′; Sigma-
Aldrich) and the negative-control siRNAs (sequence 
5′-GGCTACGTCCAGGAGCGCA-3′; GE Healthcare, 
Little Chalfont, UK) by the Lipofectamine 2000 reagent 
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(Thermo Fisher Scientific) with Opti-MEM reduced serum 
medium (Thermo Fisher Scientific), following the transfec-
tion procedure as stated with the reagent. After transfec-
tion, the cells were cultured overnight. The cells were then 
harvested in a sodium dodecyl sulfate–protease inhibitor 
buffer (65 mM Tris–HCL pH 6.8, 10% glycerol, 2% sodium 
dodecyl sulfate, 1 mM sodium orthovanadate, 1 mM 
sodium fluoride, 1 μg/mL aprotinin, 1 μg/mL leupeptin, 
1 μg/mL pepstatin A, 1 mM phenylmethylsulfonyl) and 
quantified using a DC protein-assay kit (Bio-Rad Labora-
tories Inc, Hercules, CA, USA). The standardized samples 
were finally subjected to Western blot analysis. The 
experimental procedure followed our previous method.33 
The primary antibody anti-E-cadherin was purchased from 
Sigma-Aldrich.
scanning electron microscopy 
observation
Scanning electron microscopy was used to observe the coating 
effects of the protein-coated spheres. The experimental proce-
dure used followed our previous study.23 Briefly, the protein-
coated spheres were plated onto silicon wafers and washed with 
phosphate-buffered saline once. The spheres were dehydrated 
for 5 minutes in a series of increasing ethanol solutions (30%, 
50%, 75%, 90%, and 100%). The samples were dried in a 
critical point dryer prior to examination with scanning electron 
microscopy (S4800 FEG; Hitachi, Tokyo, Japan).
Traction-force microscopy
Fabrication and stiffness characterization of Bsa-
protein micropillar matrices
In the traction-force microscopy experiments, leukemia cells 
were cultured on an array of BSA-protein micropillars. The 
protein-micropillar matrices were fabricated by a multipho-
ton, photochemical cross-linking technique in a confocal 
microscope.27,34 Before the traction-force measurement, the 
Young modulus E of the protein micropillars was measured 
by nanoindentation with AFM with a flat-end tip using a 
rate-jump method,35,36 in which an imposed rate jump ∆P. of 
the indentation force gives rise to a rate jump ∆δ
.
 of the tip 
displacement, which are related by:
 ∆ ∆ P a E
v sample
=
−



2 1 2
δ  (2)
where a is the end radius of the AFM tip and ν is the Poisson 
ratio of the sample, which is assumed to be 0.5.27 After E at 
a given set of fabrication and reagent parameters had been 
obtained from Equation 2, the bending stiffness s of the pro-
tein micropillars was calculated from the formula:37
 
s
EI
L
I
=
=
3
3
4
64
πd
 
(3)
where I is the second moment of inertia of the cross section, 
d the diameter and L the height of each micropillar. The 
stiffness of the 1 μm-diameter and 6 μm-height micropillars 
used here was estimated to be 20.44 pN/μ⋅m.27
Traction-force measurement of leukemia cells on 
Bsa-protein micropillars
In the traction-force microscopy experiments, instead of the 
separated ECM proteins, the inert protein BSA, which rarely 
interferes with most other proteins, was used to make the 
micropillars. The BSA micropillars are more representative, 
since the traction-migration behaviors are driven by the cells 
themselves. The leukemia cells cultured on the BSA micro-
pillars would stretch or contract to produce traction force F 
to bend the protein micropillars, according to:
 
F s
E
= δ
 
(4)
where δE is the elastic component of the end displacement of 
the micropillar, and s is the stiffness defined in Equation 3. 
Since the BSA-protein micropillars were viscoelastic, the 
total bending displacement δ
total
 of the micropillar would 
be larger than δE, and by assuming the Maxwell model for 
viscoelasticity,27 the δ
total
 is given as:
 
δ δ δνtotal E i= + s  (5)
where δνis is the viscous component of the bending deforma-
tion. The total deformation δ
total
 is the deflection of the protein 
micropillar before cell detachment, and upon cell detachment 
the elastic component δE will be recovered, but the viscous 
component δνis will remain as the plastic deformation. 
Therefore, the elastic deformation δE was obtained as the 
measured difference between the bending displacement of 
the micropillar before and after cell detachment.27 The cells 
were detached from the protein micropillars by incubation 
with 0.25% trypsin for 15 minutes at room temperature. The 
traction force of a single cell is the mean value of all the 
bending micropillars dragged by that cell.
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statistical analysis
Quantitative analysis regarding the cell adhesion, transwell 
migration, cell–protein/cell-binding force and traction-force 
measurement are presented as mean ± standard deviation. Two-
population t-tests were performed on the data of the adhesion 
assay, the binding-force measurement, the transwell assay, and 
the traction-force measurement. The results of Western blots 
were quantified by the software ImageJ version 1.42.
Results
adhesion measurement of PMa-treated 
leukemia cells
Before discussing the single-cell manipulation experiments 
for adhesion and traction measurement, the use of the 
conventional MTT batch-cell assay to evaluate the adhesion 
behavior of the cells on substrates precoated with different 
proteins is first described. Figure 1A shows that after treatment 
with PMA, the K562 cells gathered together, but most of them 
were still suspended. However, after the PMA treatment, many 
of the THP1 cells were stuck to the substrate and behaved as 
adherent cells. To study the interaction of leukemia cells with 
their surrounding microenvironment, the ECMPs fibronectin 
and collagen I and the adhesion protein E-cadherin, which is 
thought to be closely related to the cell–cell junction, were 
investigated. From Figure 1B, we can see that the THP1 cells 
with PMA treatment had significantly higher absorbance values 
than those without PMA treatment (P,0.05), while the absor-
bance values of K562 cells with and without PMA treatment 
Figure 1 results of the adhesion assay.
Notes: (A) Optical images of K562 and ThP1 cells with and without (control) PMa treatment; (B) cell-adhesion assay tested by protein-coated 96-well microplates using 
MTT (n=3); (C) rearrangement of the data in (B) for the K562 control and ThP1 control groups without PMa treatment. The experiments were repeated twice. results 
of two-population t-tests are indicated in (B and C).
Abbreviations: PMa, phorbol 12-myristate 13-acetate; Bsa, bovine serum albumin.
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showed no significant difference (P.0.05). The results from 
the conventional adhesion assay thus suggest that treatment 
with PMA for 48 hours would change the adhesion property 
of THP1 cells but not the K562 cells. Figure 1C shows that in 
comparison with the BSA-substrate control, the fibronectin- and 
anti-E-cadherin-coated substrates helped increase the adhesion 
ability of K562 cells without PMA treatment (P,0.05), and 
the anti-E-cadherin-coated substrates helped increase the adhe-
sion ability of THP1 cells without PMA treatment (P,0.05). 
Here, the previous inevitable trypsinization process may have 
affected the cells and their interactions with the protein-coated 
substrates and subsequently affected the statistical results, 
although any effect on viability was able to be minimized by 
optimizing the dose of trypsin and cell numbers, such as by 
minimizing proliferation in the MTT adhesion assay within a 
short time in most of the cases.
Figure 2 shows single-cell manipulation results obtained 
by using optical tweezers to measure the binding forces 
between leukemia cells and different proteins. In these 
experiments, polystyrene spheres were precoated with dif-
ferent proteins (Figure 2A), from which it can be seen that 
the spheres were fully covered by proteins. Then, a given 
sphere was trapped by the optical tweezers and brought into 
adhesive contact with a single leukemia cell stuck to the 
bottom of the confocal dish for 10 seconds. Attempts were 
then made to pull the sphere away from the cell at increas-
ing laser power, and at a critical laser power the trapping 
force was strong enough to detach the sphere from the cell, 
as shown in Figure 2B. Figure 2C shows the precalibrated 
relations of the maximum trapping force of spheres coated 
with different proteins vs the laser power, from which the 
cell–protein binding force can be obtained from the critical 
laser power for cell-sphere detachment.
Figure 2D shows the measured binding forces between 
the leukemia cells and different proteins. Compared to the 
K562 cells, the THP1 cells treated with or without PMA 
showed higher binding forces with the all the proteins studied 
except fibronectin, and this is a direct, quantitative verifica-
tion of the higher adhesion of THP1 cells that cannot be 
indicated clearly by the results in Figure 1. Two-population 
t-tests of the data in Figure 2D indicate that the PMA-treated 
K562 or THP1 cells exhibited significantly higher binding 
forces with collagen I and anti-E-cadherin proteins than 
those without PMA treatment (P,0.001). The results in 
Figure 3A and B show that after treatment with PMA for 
48 hours, the expression of both E-cadherin and vimentin 
protein of the leukemia cells increased. These results thus 
suggest that PMA promoted E-cadherin protein expression 
in both K562 and THP1 cells, and hence their binding with 
anti-E-cadherin-coated spheres. In addition, in comparison 
with the control group (BSA protein), the binding forces of 
both K562 and THP1 cells with the fibronectin, collagen I, 
and E-cadherin proteins were measured to be significantly 
higher (P,0.001), as shown in Figure 2E. It can be also seen 
from Figure 2D that both K562 and THP1 cells transfected 
with SiR-E-cadherin siRNAs exhibited significantly lower 
binding forces with the anti-E-cadherin-coated spheres than 
their nontransfected counterparts. 
The E-cadherin and vimentin protein expression of the 
leukemia cells was also directly measured by Western blots, 
as shown in Figure 3. The results in Figure 3C and D indi-
cate that transfecting SiR-E-cadherin into the leukemia cells 
inhibited E-cadherin expression. The results in Figures 2 
and 3 confirm that leukemia cells transfected with SiR-E-
cadherin siRNAs interfered with the expression of E-cadherin 
proteins on their membrane surface, and since E-cadherin 
proteins bind exclusively with E-cadherin itself or with the 
E-cadherin antibody anti-E-cadherin, binding with the anti-
E-cadherin-coated spheres became weaker. As the expres-
sion of E-cadherin protein is suppressed, the SiR-E-cadherin 
transfection should also reduce cell–cell contact in vivo.
In order to mimic the cell–cell interaction in the BM 
niche, the binding forces of K562 and THP1 cells with 
hBMSCs and hFBs were also measured by optical tweezers. 
These experiments were similar to the ones depicted in 
Figure 2, except that now a K562 or THP1 cell instead of 
a protein-coated bead was trapped by the laser and made to 
bind with an hBMSC or hFB. Figure 4A and B shows the 
force-calibration graph of trapped K562 and THP1 cells 
and the optical images of the cell–cell contact, respectively. 
In Figure 4C, the binding forces between hBMSCs and 
leukemia cells K562 and THP1 were measured to be 135.3 
and 200.4 pN, higher than the values of 69.6 and 126.4 pN 
between hFBs and leukemia cells K562 and THP1, respec-
tively. The binding forces of hBMSCs K562 and THP1 and 
hFBs K562 and THP1 treated with PMA increased to 201.5, 
314.2, 107.5, and 175.7 pN, respectively. Two-population 
t-tests indicated that the binding forces of the leukemia cells 
treated with PMA were significantly higher than those exhib-
ited by cells without the PMA treatment (P,0.001, except 
for P,0.01 in the case of the hFB THP1).
Migration measurement of PMa-treated 
leukemia cells
To evaluate the migration of the leukemia cells treated with 
and without PMA, the leukemia cells were cultured in the 
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Figure 2 Binding forces between leukemia cells and protein-coated spheres, measured using optical tweezers.
Notes: (A) seM images of protein-coated spheres. (B) Optical images of the pulling process between leukemia cells and protein-coated spheres a and d show the initial contact 
between sphere and cell. b, e and c, f show the separation process of sphere and cell when the stage was moved away from the trapped sphere. (C) Maximum trapping force 
(pN) vs laser power (mW) of protein-coated spheres (n=3 for each laser-power data point collected). (D) Measured binding forces between leukemia cells and protein-coated 
spheres (n=7 for each separated group). “sir-e-cadherin” denotes interaction between cells transfected with sir-e-cadherin sirNas and spheres coated with anti-e-cadherin. (E) 
rearrangement of data in (D) for the K562 control and ThP1 control groups without PMa treatment. results of two-population t-tests indicated in (D and E).
Abbreviations: seM, scanning electron microscopy; sirNas, small-interfering rNas; PMa, phorbol 12-myristate 13-acetate; Bsa, bovine serum albumin.
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upper chambers of the cell-invasion assay, which were pre-
coated with BSA, fibronectin, collagen I, or anti-E-cadherin. 
Figure 5A and B shows that some of the leukemia cells 
stuck to the adhesion proteins of fibronectin, collagen I, or 
anti-E-cadherin in the upper chamber and were prevented 
from getting through the holes of the cell-invasion assay. 
The adhesion proteins studied obviously helped decrease the 
migration ability of the leukemia cells. However, again the 
batch-cell assay results in Figure 5 may not provide sufficient 
quantitative information of the migration. For this reason, 
traction-force microscopy was carried out (Figure 6). In these 
experiments, cells were cultured on a matrix of BSA micropil-
lars fabricated by a multiphoton photochemical cross-linking 
technique in a confocal microscope. The migration behavior 
of the cells then caused the micropillars to bend, and the 
traction force responsible for the bending was then evaluated 
from the measured bending displacement of the micropillars, 
after the stiffness of the latter was carefully calibrated. 
Figure 6A–C shows the BSA micropillar matrix cultured 
with leukemia cells at different magnifications. Figure 6D 
shows typical K562 and THP1 cells treated with or without 
PMA on the BSA micropillar matrix. The results in Figure 6E 
show that the traction force of the THP1 cells treated with 
PMA on the BSA micropillar matrix was up to 337.4 pN, 
significantly larger than that of cells without PMA treatment 
(P,0.001). On the other hand, the traction force of the K562 
cells treated with or without PMA also exhibited a statisti-
cally significant difference (P,0.05), although the difference 
was not larger than that between THP1 cells with or without 
PMA treatment. These single-cell results suggest that the 
PMA would produce insignificant effects on the migration 
potential of K562 cells on a BSA matrix, which would agree 
with the transwell-migration assay results in Figure 5B. 
However, the single-cell results in Figure 6E clearly indicate 
that PMA treatment significantly increased traction force 
and hence would decrease the migration potential of THP1 
cells on a BSA substrate, and this contradicts the implication 
from the batch-cell assay results in Figure 5B, which show 
that the quantities of THP1 cells appearing on the other side 
of the transwell-migration assay were similar with or with-
out the PMA treatment. This difference may be due to the 
fact that the leukemia cells in the transwell-migration assay 
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Figure 3 Western blot results showing the expression of e-cadherin (e-cad) and vimentin (Vim) proteins in K562 and ThP1 cells.
Notes: (A, C) Western blots results of leukemia cells treated with and without PMa; (B, D) quantitative results of (A and B) using ImageJ software by assuming the intensity 
of the gaPDh proteins (inner control) to be 1. The experiments were performed three times, with the scatter of data indicated by error bars. results of two-population 
t-tests indicated in (B and D).
Abbreviations: PMa, phorbol 12-myristate 13-acetate; sir, small-interfering rNa; sir-e-cad, e-cadherin sirNa sequence cDh1; sir-ctrl, the negative control of small-
interfering rNa sequence. 
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had to be trypsinized in order to allow them to be counted 
at the beginning, but trypsinized nonadherent cells may not 
be precisely of the same state as cells in vivo. The results in 
Figure 6 thus indicate that the intrinsic migration ability of 
cells was not accurately reflected by the conventional batch-
cell transwell-migration assay in Figure 5.
Discussion
Accurately knowing the detailed effects of cancer treatment 
is an important step in developing effective therapies for 
leukemia treatment. The general effectiveness of a drug is 
normally assessed by its effects on cells, including adhesion,38 
migration,39 proliferation,40 differentiation,41 and death.42 
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Figure 4 Binding forces between leukemia and hBMscs/hFBs measured using optical tweezers.
Notes: (A) Maximum trapping force (pN) vs laser power (mW) of the trapped leukemia cells and hBMscs/hFBs; (B) optical images of the pulling process between leukemia 
cells and hBMscs/hFBs; (C) binding forces between leukemia cells and hBMscs/hFBs (n=7 for each separated cell–cell binding force-measurement group). results of two-
population t-tests are shown in (C).
Abbreviations: hBMSCs, human bone marrow stromal cells; hFBs, human fibroblasts; PMA, phorbol 12-myristate 13-acetate.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
7.
8.
23
0.
12
5 
on
 2
0-
Se
p-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2016:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
6542
Zhou et al





$EV
RUE
DQF
H
3 3 
3 
3 3 3 3 
3
%6$ )LEURQH
FWLQ
&ROODJH
Q,
(FDGK
HULQ
.30$
.FRQWURO 7+3FRQWURO
7+330$
P
+ROHV
.

.
30
$
7+3

7+3
30
$
)LEURQHFWLQ &ROODJHQ, (FDGKHULQ %$
PP
PPP
PPP
PPP
Figure 5 results of transwell-migration assay.
Notes: (A) Optical images of leukemia cells on the insert membrane layer of the transwell-migration assay; (B) transwell-migration measurement (n=3). The experiments 
were repeated twice. results of two-population t-tests shown in (B).
Abbreviations: PMa, phorbol 12-myristate 13-acetate; Bsa, bovine serum albumin.
For the specific issue of cancer metastasis, however, a desir-
able treatment outcome should be linked to the intrinsic 
ability of the drug to promote cell adhesion and suppress cell 
migration, so that the release of diseased leukocytes from 
the BM into the bloodstream would be limited.43 Therefore, 
accurately knowing the interaction forces between cells 
and cell–proteins would allow better comprehension of the 
potential therapeutic effect of drug candidates.44
However, many agents, such as the PMA studied here, which 
was used in clinical trials for hematologic malignancy,45,46 
are activators in the signaling transduction pathway of 
PKC,47 which can affect not only the adhesion and migration 
behavior of cells but also their proliferation, differentiation, 
and death. For such agents, the conventional batch-cell adhe-
sion assays (such as that shown in Figure 1), may not give 
a precise indication of the intrinsic cell adhesion and hence 
metastatic potential, since cell proliferation is also affected 
by the treatment and the cell adhesion may be affected by 
the trypsinization. Similarly, for transwell migration, simple 
measurement of the number of cells that appear on the other 
side of a batch-cell transwell migration (ie, Figure 5) assay 
may also give misleading information on the intrinsic cell-
migration effect of the treatment. Also, although Western 
blot can be used to measure the protein markers related to 
cell adhesion or migration, it is an indirect method yielding 
only qualitative instead of quantitative indication for adhe-
sion or migration. For such treatments that produce multiple 
cellular effects, the most reliable method is thus a single-cell 
assay that allows direct measurement of the cell adhesion 
or traction on a substrate coated with the cell–proteins in 
question. The present work illustrates that quantitative 
measurement of the interaction or traction forces between 
cells and cell–proteins can be directly made using optical 
tweezers or traction-force microscopy. The interaction 
forces measured this way provide the most direct indica-
tion of the effect of a given drug or agent on cell-adhesion 
or -migration properties.
The BMS microenvironment nurtures the hematopoietic 
and leukemia cells and secretes growth factors and matrix 
proteins that regulate the interaction of hematopoietic and 
leukemia cells with hBMSCs.48 In Figures 2 and 4, the bind-
ing forces of leukemia cells with the ECMP (fibronectin and 
collagen I), as well as the adhesion proteins E-cadherin, 
hBMSCs, and hFBs, were measured, and the results showed 
that the adhesion of leukemia cells was regulated by their 
surrounding microenvironment. The binding force measured 
by optical tweezers truly represents the interaction between 
leukemia cells and their microenvironment. Leukemia cells 
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Figure 6 Traction-force measurements of K562 and ThP1 cells with and without PMa treatment using multiphoton photochemical cross-linking-based fabrication.
Notes: (A–D) Protein micropillar matrix and leukemia cells at different scales; (E) traction force of K562 and ThP1 cells with and without PMa treatment on the Bsa 
protein micropillar matrix. Ten cells for each group were measured. The results of two-population t-tests shown in (E).
Abbreviations: PMa, phorbol 12-myristate 13-acetate; Bsa, bovine serum albumin.
are thought to arise from the HSCs, caused by mutations 
and/or selective expression of genes that enhance their 
limited self-renewal capabilities.49 Leukemia cells exhibit 
low expression of E-cadherin, loss of homophilic adhesion,7 
and decreased cell–cell interaction, which are factors that 
may promote their escape from the BM niche. The Western 
blots in Figure 3A and B show that after treatment with 
PMA, both K562 and THP1 cells showed higher E-cadherin 
protein expression. Strong adhesion between leukemia cells 
and E-cadherin can also be seen from Figure 2. The role of 
E-cadherin in cell–cell interaction was further examined by 
using SiRNA interference. As shown in Figure 3C and D, 
SiR-E-cadherin-interfered leukemia cells exhibited low 
expression of E-cadherin protein, as detected by Western 
blot, and Figure 2 shows that the optical tweezers were able 
to detect sensitively the reduction in binding forces with the 
anti-E-cadherin proteins. A high expression of the mesenchy-
mal intermediate filament protein vimentin was also detected 
by Western blot after PMA treatment, which is consistent 
with other findings.50
Although optical tweezers21 and traction-force 
microscopy51 have been around for some time, there is still 
plenty of room for the development of new applications and 
experimental protocols of these techniques. In the present 
work, a detailed protocol for the direct measurement of 
cell–protein and cell–cell interactions by optical tweezers 
was demonstrated, in which the sphere-coating and contact 
procedures can make the measurement more repeatable and 
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hence offering a more stable outcome. Furthermore, in the 
traction-force microscopy experiments, a novel protocol 
involving protein micropillar matrices27 fabricated by a mul-
tiphoton, photochemical cross-linking technique,27 combined 
with the rate-jump method,29 which is a far more reliable 
method for measuring the stiffness of viscoelastic protein 
pillars, enabled more accurate results to be obtained.
Finally, the observation that the transwell migration of 
leukemia cells driven by chemotaxis was suppressed by the 
ECMPs fibronectin and collagen I or anti-E-cadherin suggests 
that both alteration of the surrounding microenvironment and 
the membrane-surface proteins of leukemia cells could lead 
to a change of migration. The traction forces measured in 
Figure 6 showed that THP1 cells had much stronger interac-
tion with the BSA substrate than the K562 cells and behaved 
like adherent cells. This is consistent with Figure 1A, where 
many THP1 cells treated with PMA were stuck to the sub-
strate. The traction-force microscopy technique illustrated in 
Figure 6 can be used to study cells in contact with a substrate 
during migration, in order to evaluate the behavior of cells 
in therapy.
Conclusion
Optical tweezers and traction-force microscopy were applied 
to measure quantitatively the pico-Newton level mechanical 
forces in single cell–protein and cell–cell interactions. PMA 
treatment was found to promote the interaction of K562 or 
THP1 leukemia cells with ECMPs, BMSCs, or hFBs. The 
results indicate that PMA treatment increases the adhesion 
and decreases the migration of K562 and THP1 cells in their 
microenvironment.
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